ロード中...
Modulation of Trabectedin (ET-743) Hepatobiliary Disposition by Multidrug Resistance-Associated Proteins (Mrps) May Prevent Hepatotoxicity
Trabectedin is a promising anticancer agent, but dose-limiting hepatotoxicity was observed during phase I/II clinical trials. Dexamethasone (DEX) has been shown to significantly reduce trabectedin-mediated hepatotoxicity. The current study was designed to assess the capability of sandwich-cultured p...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2007
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2572823/ https://ncbi.nlm.nih.gov/pubmed/18191164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.taap.2007.11.020 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|